1 The hypotensive effect of imidazoline-like drugs, such as clonidine, was attributed both to a 2 -adrenergic receptors and nonadrenergic imidazoline receptors, which are divided into I 1 , I 2 and I 3 subtypes. 2 We have recently synthesized a derivative of (2-(2-chloro-4-iodo-phenylamino)-5-methyl-pyrroline (LNP 911), the first high-affinity and selective ligand for I 1 receptors (I 1 R), with a photoactivable function (LNP 906). 3 This work aims to test whether this derivative retained the binding properties of LNP 911 and bound irreversibly to I 1 R. 4 Binding studies showed that LNP 906 exhibited nanomolar affinity for I 1 R and was selective for I 1 R over I 2 receptors and a 2 -adrenergic receptors (a 2 Ars). 5 Upon exposure to u.v. light, LNP 906 irreversibly blocked the binding of [ 125 I]-paraiodoclonidine (PIC) to I 1 R, time-and dose-dependently, on PC12 cell membranes and interacted with I 1 R in a reversible and competitive manner in the absence of light. Pharmacological studies showed that this blockade was prevented by the concomitant presence of rilmenidine (a well-known I 1 agonist), but not by rauwolscine (an a 2 antagonist). 6 Finally, LNP 906 clearly antagonized the decrease in forskolin-stimulated cAMP level induced by rilmenidine, but not by melatonin. 7 These results indicate that LNP 906 is the first high-affinity and selective photoaffinity ligand for I 1 R and that it behaves as an I 1 R antagonist.
Introduction
There is a large body of evidence which supports the view that the hypotensive action of clonidine involves a 2 -adrenoreceptors (for a review, see Bousquet & Feldman, 1999) . However, the central hypotensive effect of clonidine and related compounds was shown to be mediated through nonadrenergic imidazoline receptors also (Bousquet et al., 1984; Ernsberger et al., 1990; Molderings et al., 1993; Piletz & Sletten, 1993) . It is now widely recognized that mammalian imidazoline-binding sites can be divided into I 1 and I 2 subtypes, and recently a third class, I 3 sites, has also been proposed (Regunathan & Reis, 1996; Ernsberger, 1999; Bousquet et al., 2000) . Cloning strategies and biochemical studies have assigned I 2 -binding sites (I 2 BS) to a modulatory site on monoamine oxidases A and B (Gargalidis-Moudanos & Parini, 1995; Tesson et al., 1995) . The existence of I 3 receptors (non-I 1 non-I 2 ) has been suggested according to the insulin release modulatory properties of some imidazolines in b pancreatic cells (Chan et al., 1994; Zaitsev et al., 1996) . The I 1 receptor (I 1 R) is a plasma membrane receptor protein (Heemskerk et al., 1998) , which has been also detected in human platelets, bovine chromaffin cells and PC12 cells (Molderings et al., 1993; Piletz et al., 1996; Greney et al., 2000) . Transduction pathways have already been associated with this receptor in the PC12 cells: activation of a phosphocholine-specific phospholipase C (Separovic et al, 1996) and inhibition of an adenylate cyclase (Greney et al., 2000) . Moreover, pharmacological studies have shown that this receptor is involved in several functions such as regulation of the cardiovascular function (Bousquet et al., 1984; Ernsberger et al., 1990) , modulation of the ocular pressure (Ogidigben et al., 2001) and renal sodium excretion (Smyth & Penner, 1999) .
So far, all the radioligands used to characterize the I 1 receptors were 'hybrid' molecules able to bind with similar affinities both to I 1 receptors and to a 2 -adrenoceptors (Molderings et al., 1993; Piletz et al., 1996) . In an effort to fully characterize these receptors, we developed a series of new imidazoline analogs with high selectivity and affinity for I 1 receptors. We have recently synthesized a series of pyrroline analogs with no detectable affinities for I 2 BS and for a 2 -adrenoceptors (Schann et al., 2001) . Among these pyrroline compounds, 2-(2-chloro-4-iodo-phenylamino)-5-methyl-pyrroline (LNP 911) was found to be highly selective for I 1 R and interestingly exhibited nanomolar affinity for these receptors (Urosevic et al., 2002) .
A ligand capable of binding irreversibly at I 1 R is important to investigate the molecular characteristics of this receptor; however, no such ligand is currently available. To fill this gap, we have synthesized a derivative of LNP 911 with a photoactivable function (2-(5-azido-2-chloro-4-iodo-phenylamino)-5-methyl-pyrroline or LNP 906). In this report, we tested whether this derivative retained the binding properties of LNP 911 (i.e. high affinity and selectivity for I 1 R) and demonstrated that LNP 906 binds irreversibly to this receptor. The results showed that LNP 906 binds to I 1 receptors with high affinity and high selectivity. Moreover, LNP 906 interacts with I 1 receptors in a reversible and competitive manner in the dark, but binds irreversibly to I 1 receptors after exposure to u.v. light (254 nm) of membrane preparations of rat PC12 cells. In this study, PC12 cells were used because it was previously shown in binding and hybridization studies that these cells lack a 2 -adrenoreceptors and I 2 -binding sites (Piletz et al., 1991; Bricca et al., 1994; Separovic et al., 1996; Greney et al., 2000) . Therefore, PC12 cells represent an interesting model to study the I 1 receptors in the absence of a 2 -adrenoreceptors and I 2 -binding sites. The inactivation of I 1 receptors by LNP 906 was clearly dependent on the time of exposure to UV light and on the concentration of LNP 906 present during photolysis. LNP 906 was able to prevent the decrease in forskolin-stimulated cAMP levels induced by agonist on I 1 R; it therefore behaved as an I 1 antagonist. Thus, LNP 906 is the first highly selective photoaffinity ligand exhibiting a nanomolar affinity for I 1 R, and should prove useful for studies of the structure and function of I 1 receptors.
Methods

LNP 906 synthesis
LNP 906 was synthesized from LNP 911, which was previously synthesized in our laboratory (Table 1) and characterized as the first high-affinity ligand selective for the I 1 receptors (Urosevic et al. , 2002) . LNP 906 is an analog of LNP 911 with an azido group on C5 of the aromatic ring. Briefly, LNP 906 was obtained by reaction of (2-(5-amino-2-chloro-4-iodophenylamino)-5-methyl-pyrroline) with NaNO 2 in the presence of HCl 4 N at 01C. After agitation of 45 min at the same temperature, NaN 3 was added slowly to the intermediate at room temperature, and the compound was then extracted with CH 2 Cl 2 in the presence of K 2 CO 3 ; the azido compound was finally obtained after washing and drying of the organic phase and separation by chromatography.
Radioligand-binding assays I 1 -binding sites PC12 cell membrane preparation and binding assays with [ 125 I]-PIC on PC12 cell membranes were performed as described elsewhere (Greney et al., 2000) . Binding assays with [ 125 I]-LNP 911 on PC12 cell membranes were all performed at 251C and were as follows. Incubation was initiated by the addition of membranes (20-50 mg of protein) in a final volume of 250 ml of Tris-HEPES buffer (50 mM Tris-HEPES, pH 7.7, 0.5 mM EDTA, 0.5 mM EGTA and 0.5 mM MgCl 2 ) and was carried out at 251C during 60 min (equilibrium conditions). The reaction was stopped by rapid vacuum filtration through GF/B glass fibre filters with a Brandel harvester, followed by three rapid washes of the filters with 3 ml of ice-cold 50 mM Tris-HCl buffer, pH 7.4. Radioactivity retained on the dried filters was determined in a Minaxi gamma counter (Packard, Meriden, CT, U.S.A. I 2 -binding sites Rabbit kidney membranes preparation and affinities of drugs were performed as described (Pigini et al., 1997) . Nonspecific binding was determined with 10 mM cirazoline for [
3 H]-idazoxan binding. Radioactivity retained on the filters was determined in a beta TriCarb counter (Packard).
a 2 -binding assays CHO membrane preparation is as described in the following (Piletz et al., 1996) 
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Photoaffinity labelling
u.v. light characteristics of LNP 906 were determined and stability of the probes was assessed by hourly sequential u.v. measurement over a period of 4 h in the binding buffer at 251C. The LNP 906 is stable for up to 4 h in the absence of light and shows spectral characteristics appropriate for direct irradiation photoactivation (Goeldner & Hirth, 1980; Peng et al., 1994) with a strong absorption at 254 nm. To investigate the photoaffinity labelling, the incubation was performed in greater volumes (minimum 2 ml tubes) at 251C. The photoaffinity assay was performed as follows: after B60 min incubation in the dark (which is the period required for the binding of an I 1 ligand to reach equilibrium on I 1 R) under dim red light with LNP 906 20 mM, the membranes were placed on ice in an opened glass Petri dish and irradiated for 15 min at a distance of 2 cm with a Bioblock VL-6LC UV 12 W transilluminator. These photoactivable ligand concentrations and the photolysis times were found to give an optimal photolabelling yield in pilot experiments. These conditions and the photolabelling technique was adapted from that described elsewhere (Kawahara et al., 1985; Ernsberger & U'Prichard, 1986; Lanier et al., 1993) . For the pharmacological studies of the irreversible binding, membranes were pre-incubated with the ligand at a concentration of 20 mM for 60 min at 251C, in the presence or absence of the photoactivable ligand. After irradiation, the samples were then washed in 25 ml of an ice-cold buffer (5 mM Tris-HEPES, pH 7.7, 0.5 mM EDTA, 0.5 mM EGTA, 0.5 mM MgCl 2 and NaCl 100 mM), homogenized with 10 strokes of a glass Dounce homogenizer, and centrifuged at 60,000 Â g for 10 min at 41C. The pellet was washed twice in 25 ml of cold Tris-HEPES buffer and centrifuged. Pellets were at least resuspended in 2 ml of the same buffer and used in receptor-binding assays.
The washing procedure was validated in pilot experiments, that is, membranes were incubated in the dark up to equilibrium with or without 20 mM LNP 906 (control) for 60 min, but were not irradiated. The samples were then washed several times by centrifugation with the binding buffer at 41C.
cAMP experiments
cAMP experiments were conducted as previously described, but in the dark (Greney et al., 2000) . In antagonism experiments, LNP 906 (10 À5 M) was added to the medium 10 min before adding other drugs. The radioreceptor assay kit for measuring cAMP levels (Amersham, France) was used according to the instructions of the manufacturer.
Drugs and supplies
Dulbecco's modified Eagle's medium (DMEM), foetal bovine serum (FBS), penicillin and streptomycin were obtained from Life Technologies (Cergy-Pontoise, France). Rilmenidine was a gift from Laboratories Servier (Courbevoie, France). 
Protein assay
Protein concentrations were determined according to the method of Bradford (1976) with bovine serum albumin as standard.
Data analysis
Data from kinetic, saturation and competition experiments were analysed using the least-square-fitting program GraphPad Prism (GraphPad Software Inc.). IC 50 values were calculated according to Cheng and Prusoff equation (Cheng & Prusoff, 1973) . In binding experiments, the significance of the improvement of fit obtained by a two-site equation over one-site equation was analysed by F-statistics (partial F-test). The statistical significance of differences was analysed by Student's t-tests. Results are expressed as the mean values7-s.e.m.
For all other cases, the statistical significance of differences was analysed by a one-way factorial ANOVA with post hoc tests of Bonferroni (Statsview Software, Abacus Concepts), and was reached when Po0.05, n denoted the number of experiments.
Results
Binding characteristics of unlabelled LNP 906
The binding characteristics of LNP 906 at the I 1 -, I 2 -and a 2 -binding sites were measured in the dark.
The The results showed that the UV irradiation (254 nm) by itself only slightly altered the binding sites at 5 and 15 min (9672% of the control (P ¼ 0.77, n ¼ 4) and 9273% of the control (P ¼ 0.58, n ¼ 4), respectively) and moderately at 30 and 45 min (8574% of the control (P ¼ 0.28, n ¼ 4); 7575% of the control (P ¼ 0.073, n ¼ 4, respectively), suggesting that imidazoline-binding sites themselves are, to some extent, sensitive to these conditions of irradiation ( Figure 3 ). Membranes photolysed in the presence of the azido compound LNP 906 displayed a progressive decreased binding capacity for [ Effect of the concentration of LNP 906 on the photolysed I 1 receptors
In Figure 4 , the results of several experiments are shown, in which the duration of ultraviolet exposure was held constant (15 min) whereas the concentration of LNP 906 was changed. Consistent with a receptor-ligand interaction, the photolytic inactivation of I 1 receptors by LNP 906 was concentration dependent (8877% of the control (P ¼ 0.13, n ¼ 5), 4077% of the control (Po0.01, n ¼ 5) and 1776% of the control (Po0.01, n ¼ 5) at 2, 20 and 200 mM, respectively). No 
Protection against the loss of the [ 125 I]-PIC-specific binding on photolysed I 1 receptors
The pharmacology of I 1 receptor inactivation by LNP 906 was studied, and the results are expressed in Figure 5 . In these experiments, the receptors were exposed to LNP 906 alone or to combinations of LNP 906 and other ligands. Subsequently, the free and reversibly bound ligands were removed by washing, and the specific binding of [ 
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LNP 906 is a functional I 1 R antagonist
We tested the effect of LNP 906 on the cAMP transduction pathway associated with the I 1 receptors in the PC12 cells (Greney et al., 2000) . In a first series of experiments, we tested the effects of LNP 906 at 10 À5 M alone or in combination with rilmenidine, an I 1 selective ligand (Figure 6a ). LNP 906 (10 À5 M) had no significant effect on its own on the basal (8277 and 8177 fmol min À1 /10 5 cells (P ¼ 0.17, n ¼ 4) in the absence and presence of LNP 906, respectively) and forskolinstimulated cAMP level (222719 and 226721 fmol min À1 /10 5 cells (P ¼ 0.5, n ¼ 4) in the absence and presence of LNP 906, respectively) in the cells, as expected for an antagonist. On the other hand, rilmenidine proved able to decrease slightly, but significantly and dose-dependently, the forskolin-stimulated accumulation of cAMP in the cells (1274 (P ¼ 0.1, n ¼ 4), 1571 (Po0.05, n ¼ 4), 2172 (P ¼ 0.01, n ¼ 4) and 3879% (Po0.01, n ¼ 4) of inhibition only for the concentration range of 10
À7
-10 À4 M of rilmenidine, respectively, in the absence of LNP 906), acting thus as agonist on this pathway (Figure 6a ) (as previously shown, Greney et al., 2000) . In all, 100% of the control represents the value in the presence of forskolin, which was only 222719 fmol min À1 /10 5 cells. However, when LNP 906 (10 À5 M) was added 10 min before rilmenidine, it prevented the decrease in forskolin-stimulated cAMP level obtained with this agonist: 170.4 (P ¼ 0.064, n ¼ 4), 270.5 (Po0.05, n ¼ 4), 872 (Po0.05, n ¼ 4) and 1273% (Po0.01, n ¼ 4) of inhibition in the presence of LNP 906.
In order to demonstrate the specificity of action of LNP 906, we tested whether LNP 906 has antagonist properties towards melatonin, a neuromodulator proved able to suppress the PC12 cell growth and death by inhibiting the cAMP formation at MT 1 -specific receptors on cell surface (Roth et al., 1997; . As expected, melatonin significantly decreased the cAMP levels up to 1274% of inhibition at 10 À6 M (Po0.01, n ¼ 4) and 3274% of inhibition at 10 À5 M (Po0.01, n ¼ 4). This effect of melatonin was not significantly antagonized by LNP 906 (1274 of inhibition at 10 À6 M of melatonin (P ¼ 0.95, n ¼ 4) and 3476 of inhibition at 10 À5 M of melatonin (P ¼ 0.69, n ¼ 4) in the presence of LNP 906) (Figure 6b ).
Discussion and conclusions
So far, the most common radiolabelled radioligands used in the field of imidazoline receptors are [ (Table 1) (Piletz et al., 1991; Molderings et al., 1993; Bricca et al., 1994) ; unfortunately, they bind to both a 2 and I 1 receptors. Therefore, highly selective ligands were needed for these receptors.
One of them was synthesized and characterized in our laboratory: LNP 509 exhibited a high selectivity for the I 1 R as compared to a 2 -ARs and decreased blood pressure (Schann et al., 2001) . Nevertheless, its affinity for I 1 receptors was not high enough to use it as a tool relevant for molecular studies of the I 1 receptors. Later on, in a series of pyrroline compounds, the LNP 911 has been selected as a high-affinity I 1 receptor ligand (Table 1 ). The radioiodinated derivative of LNP 911 was shown to be the first radioligand highly selective for I 1 receptors (Greney et al., 2002) .
Therefore, LNP 911 appeared as a prototypic pharmacological tool. Nevertheless, in the range of the tools necessary for studying the I 1 receptors, a photoaffinity ligand was still missing. In order to obtain such a photoaffinity ligand, we prepared the azido derivative of LNP 911, LNP 906. We report here that LNP 906 exhibited high affinity for I 1 -binding sites of PC12 membrane preparations. Photoaffinity labelling has been useful in the identification of a 1 -adrenoreceptors (Hess et al., 1983; Leeb-Lundberg et al., 1984) , a 2 -adrenoreceptors (Regan et al., 1985) , b-adrenoreceptors (Lavin et al., 1981; Rashidbaigi & Ruoho, 1981) or I 2 receptors (Lanier et al., 1993; Dontenwill et al., 1997; Coates et al., 2000) . Irreversible ligands allow complete knockout of one particular site. Moreover, irreversible ligands act as antagonists at these receptors.
The present study demonstrates that the novel compound LNP 906 is the first potent photoaffinity probe selective for the I 1 receptors, which interacts with I 1 receptors in a reversible and competitive manner in the absence of light, but interacts with the I 1 receptor in an irreversible manner when exposed to ultraviolet light. The inactivation of I 1 receptors by LNP 906 was clearly dependent on exposure to u.v. light and on the concentration of LNP 906 present during photolysis.
The selectivity of LNP 906 for I 1 R versus I 2 BS and a 2 -adrenoceptors was checked by different ways in the absence of 
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The first photoaffinity ligand for I 1 receptors light: (1) in rabbit kidney membranes, where I 2 BS are largely expressed (Coupry et al., 1990) (Greney et al., 2002) . It was important to establish that LNP 906 and LNP 911 are able to bind to the same allosteric modulatory sites of the I 1 R. To check this hypothesis, the effect of 50 mM LNP 906 on the kinetic dissociation of the [ In fact, the pharmacological mechanism of action of unphotolysed LNP 906 was also explored in functional experiments in which rilmenidine and melatonin exhibited agonist properties by decreasing the cAMP level in the cell (Greney et al., 2000; Roth et al., 2001) . It is interesting to note that rilmenidine decreased cAMP level (present data), whereas clonidine was inactive in the same assay (Greney et al., 2000) . As far as several transduction pathways are associated with a unique receptor, it is not uncommon that a particular drug acts as an agonist on one pathway but as an antagonist on another one et vice versa of course (for discussion on this point, see Greney et al. (2000) and Gerhardt et al. (1999) ). When LNP 906 (10 À5 M) was added 10 min before these compounds (10 À5 M), it prevented the decrease in forskolin-stimulated cAMP level caused by rilmenidine for the concentration range of 10
À7
-10 À4 M. In these cells, rather high concentrations of rilmenidine are needed to significantly reduce the cAMP level; this is preferably due to the fact that the maximal inhibitory effect of the imidazoline compounds on the cAMP pathway is quite weak (Greney et al., 2000) .
However, LNP 906 did not influence the decrease in forskolin-stimulated cAMP level induced by melatonin, the natural agonist for melatonin MT 1 receptors. Moreover, LNP 906 was inactive by itself on the adenylate cyclase transduction pathway, suggesting that unphotolysed LNP 906 is a selective antagonist on the cAMP-dependent cell surface I 1 receptors.
We have previously shown that the low-affinity sites labelled by rilmenidine belong to the I 1 R. These low-affinity sites were shown to correspond to the G-protein uncoupled state of the receptor (Greney et al., 2000 (Greney et al., , 2002 . In the present work, we show that LNP 906 prevented the effects of rilmenidine on the cAMP pathway and that rilmenidine conversely prevented the binding interaction between LNP 906 and [ 125 I] PIC. Therefore, as far as I 1 R of PC12 cells are defined as receptors on which rilmenidine, moxonidine and other imidazoline compounds are able to bind, one can assume that the low-affinity sites of rilmenidine and LNP 906 are or, at least, belong to the I 1 receptor.
When irradiated with u.v. light, LNP 906 is highly photosensitive. It completely decomposes over 5 min irradiation as determined on thin layer chromatography, forming spots distinct the nonphotolysed form (data not shown). Therefore, LNP 906 has the features of a relevant photoaffinity probe (Regan et al., 1985; Kotzyba-Hibert et al., 1996) . The maximum I 1 receptor blockade obtained by photolysis in the presence of LNP 906 by photolysis reached 70%. This feature compares favourably with the 60-80% decreases that were reported in similar studies using nonradiolabelled photoaffinity ligands of b-adrenoreceptors (Lavin et al., 1981; Burgermeister et al., 1982) . Extensive washing of membranes preincubated with 20 mM of LNP 906 did not change the specific binding of [ ]-PIC, in the absence of photolysis, 99.8% of the original specific binding was recovered by the washing procedure. Nevertheless, measurement of the actual extent of the covalent incorporation would require a radiolabelled derivative of LNP 906. The inactivation of I 1 receptors by LNP 906 was clearly dependent on exposure to UV light with a maximal effect at 45 min of irradiation. A 15 min duration of irradiation was then used in all our photolabelling assays because, at this time, a 50% blockade of I 1 R was observed and because the membranes were only slightly sensitive to these conditions of ultra-violet light exposure. A concentration dependence of the photoinactivation of I 1 receptors by LNP 906 following exposure to short wavelength ultraviolet light was also observed. So far we cannot explain the discrepancy observed between the nanomolar IC 50 obtained when LNP 906 was used as a competitor in the absence of light and the micromolar concentration of LNP 906, which was required to irreversibly block the binding at I 1 Rs after irradiation. A possibility is that the photolysis may alter to some extent the interaction between the ligand and the receptor protein. Such a photolysis-induced phenomenon has already been reported with various phoaffinity probes (Ernsberger & U'Prichard, 1986; Dontenwill et al., 1997) . Therefore, these data demonstrate the specificity of I 1 receptor labelling
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The first photoaffinity ligand for I 1 receptorsby LNP 906, the requirement of ultraviolet light, and a time and dose dependence for receptor inactivation, which parallels the photolytic decomposition of the azide.
In conclusion, LNP 906 is the first highly selective photoaffinity ligand exhibiting a nanomolar affinity for I 1 R. Our results indicate that, upon photolysis, LNP 906 irreversibly labelled the I 1 -binding sites with efficacy and specificity. The blocking effect of photolysed LNP 906 on the [ 125 I]-PICspecific binding was time and concentration dependent. LNP 906 blocked the decrease of the forskolin-stimulated cAMP level induced by rilmenidine but not by melatonin, suggesting that it acted as a selective I 1 antagonist. Taken together, these results are consistent with LNP 906 being of a photoaffinity probe. It will be useful to identify and investigate in detail the structure and functions of I 1 receptors even in tissues or cells expressing different imidazoline-binding proteins (a 2 -adrenoceptors or I 2 BS). A radiolabelled form of LNP 906 may prove useful in isolating the I 1 receptor.
